# Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

> **NCT03836209** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PrECOG, LLC.** · enrollment: 181 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gilteritinib
- **DRUG:** Midostaurin
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03836209
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-06
- **Primary completion:** 2023-10-17
- **Final completion:** 2026-12
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836209, "Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03836209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*